NCT05498467 is a Phase 3 clinical trial of Anakinra in Allergic Contact Dermatitis, sponsored by Herlev and Gentofte Hospital.

Who is sponsoring NCT05498467?

NCT05498467 is sponsored by Herlev and Gentofte Hospital.

What drugs are being tested in NCT05498467?

Interventions in NCT05498467: Anakinra, Sodium Chloride 9mg/ml Injection.

What condition does NCT05498467 study?

NCT05498467 studies Allergic Contact Dermatitis.

Is NCT05498467 still recruiting?

NCT05498467 is currently completed. Last updated 20 May 2025.

Are results published for NCT05498467?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-05-20 · How we verify

NCT05498467

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis

Completed Phase 3 Results posted Last updated 20 May 2025

What this trial tests

Phase 3 trial testing Anakinra in Allergic Contact Dermatitis in 20 participants. Completed in 1 August 2024.

Timeline

11 October 2022

Primary endpoint
1 December 2023

1 August 2024

Quick facts

Lead sponsor	Herlev and Gentofte Hospital
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	20
Start date	11 October 2022
Primary completion	1 December 2023
Estimated completion	1 August 2024
Sites	1 location across Denmark

Drugs / interventions tested

Anakinra (ANAKINRA) — full drug profile →
Sodium Chloride 9mg/ml Injection

Conditions studied

Allergic Contact Dermatitis — all drugs for Allergic Contact Dermatitis →

Sponsor

Herlev and Gentofte Hospital

Who can join

Adults 18 to 65, any sex, with Allergic Contact Dermatitis. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Clinical Reaction Primary · 2 months

Number of participants with a lower clinical ICDRGscoring in the active treatment group compared to placebo

Group	Value	95% CI
Anakinra	0
Placebo	0
Anakinra	12
Placebo	8

Sponsor's own description

The study will investigate if Anakinra can ameliorate allergic contact dermatitis in participants with known nickel allergy

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Allergic Contact Dermatitis: Immunopathology and Potential Therapeutic Strategies.
Funch AB, Geisler C, Bonefeld CM. · · 2025 · PMID 41156043 · DOI 10.3390/jcm14207175

Verify or expand the search:

Other trials of Anakinra

Trials testing the same drug.

NCT06381661 — Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Tra · Phase 2 · not yet recruiting
NCT07281027 — COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE" · Phase 3 · not yet recruiting
NCT07191444 — A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease · recruiting
NCT06666335 — A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF · Phase 4 · not yet recruiting
NCT06697431 — Non Inferiority KawasakI Trial With Anakinra · Phase 4 · not yet recruiting

Other recruiting trials for Allergic Contact Dermatitis

Currently open trials in the same condition.

NCT06529913 — Environmental Exposure to Heavy Metals, Nanoparticles, and Emergent Contaminants and Risk of Allergic Diseases · NA · recruiting
NCT05535738 — Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation · Phase 2, PHASE3 · recruiting
NCT03935971 — The Effects of Dupilumab on Allergic Contact Dermatitis · Phase 4 · active not recruiting

Other Herlev and Gentofte Hospital trials

Trials by the same sponsor.

NCT07493590 — CAPTURE-HFpEF: National Study of Identification and Phenotyping of Heart Failure With Preserved Ejection Fraction · not yet recruiting
NCT07321964 — The Effect of a Digital MediYoga Program on Quality of Life, Blood Pressure and Heart Rate Among Patients With Atrial Fi · NA · recruiting
NCT06706661 — Implementation of Nutritional Efforts on Discharged Older Patients · NA · recruiting
NCT06618417 — Evaluating the Impact of Home-Based Sleep Apnea Diagnostic on Well-Being, Health Behavior, and AF Load in Patients with · NA · recruiting
NCT06642272 — A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Hea · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05498467 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Herlev and Gentofte Hospital
Last refreshed: 20 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05498467.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing